Ritonavir

Drug Profile

Ritonavir

Alternative Names: A 84538; ABT 538; Norvir

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; AbbVie; Gilead Sciences; RP Scherer
  • Class Amides; Antiretrovirals; Carbamates; Small molecules; Thiazoles
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 30 Nov 2015 Phase-III clinical trials in HIV infections (Treatment-experienced, Combination therapy) in USA (PO) (NCT02603107)
  • 30 Nov 2014 Ritonavir licensed to Medicines Patent Pool worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top